Literature DB >> 16973109

Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Lotus Mallbris1, Christopher T Ritchlin, Mona Ståhle.   

Abstract

Psoriasis is one of the common complex disorders in Western world, affecting 2% to 3% of the population. Recent studies indicate that psoriasis is associated with an increased risk of comorbidity and mortality compared to the general population. It appears that patients with psoriasis have a higher prevalence of metabolic disorders such as diabetes, hypertension, obesity, and hyperlipidemia, as well as a higher frequency of cigarette smoking. These concomitant diseases can complicate the treatment of psoriasis. Even though the etiology of these associations is elusive, physicians should be aware of them and take active steps to reduce the risk profiles of patients with psoriasis and psoriatic arthritis, in order to lessen mortality and comorbidity.

Entities:  

Mesh:

Year:  2006        PMID: 16973109     DOI: 10.1007/s11926-006-0065-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  60 in total

Review 1.  Treatment of psoriasis. Part 2. Systemic therapies.

Authors:  M Lebwohl; S Ali
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

2.  Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey.

Authors:  Donna K Arnett; Paul G McGovern; David R Jacobs; Eyal Shahar; Sue Duval; Henry Blackburn; Russell V Luepker
Journal:  Am J Epidemiol       Date:  2002-11-15       Impact factor: 4.897

3.  Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Clin Chim Acta       Date:  2001-01       Impact factor: 3.786

4.  High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients.

Authors:  P Ena; P Madeddu; N Glorioso; D Cerimele; A Rappelli
Journal:  Acta Cardiol       Date:  1985       Impact factor: 1.718

5.  Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease.

Authors:  S M Jones; C P Harris; J Lloyd; C A Stirling; J P Reckless; N J McHugh
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  The inflammatory response in mild and in severe psoriasis.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

7.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

8.  C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.

Authors:  Jian-Jun Li; Chun-Hong Fang
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

9.  Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions.

Authors:  Alexandra Aicher; Christopher Heeschen; Mariette Mohaupt; John P Cooke; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

10.  Dyslipoproteinemia in the course of active rheumatoid arthritis.

Authors:  M B Lazarevic; J Vitic; V Mladenovic; B L Myones; J L Skosey; W I Swedler
Journal:  Semin Arthritis Rheum       Date:  1992-12       Impact factor: 5.532

View more
  34 in total

1.  Smoking and the risk of psoriasis in women: Nurses' Health Study II.

Authors:  Arathi R Setty; Gary Curhan; Hyon K Choi
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

2.  Clinico-biochemical correlation between psoriasis and insulin resistance.

Authors:  Suparna Dhara; Anindya Dasgupta; Jayanta Kumar Rout; Ushasi Banerjee; Sayantan Dasgupta; Arindam Ghosh
Journal:  Indian J Clin Biochem       Date:  2014-01-23

Review 3.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Ustekinumab in psoriatic arthritis and related phenotypes.

Authors:  Isobel Dobbin-Sears; Janet Roberts; Darren D O'Rielly; Proton Rahman
Journal:  Ther Adv Chronic Dis       Date:  2018-06-13       Impact factor: 5.091

Review 5.  Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.

Authors:  Raseen Tariq; Page Axley; Ashwani K Singal
Journal:  J Clin Exp Hepatol       Date:  2019-07-25

Review 6.  Managing moderate-to-severe psoriasis in the elderly.

Authors:  Nicola Balato; Cataldo Patruno; Maddalena Napolitano; Angela Patrì; Fabio Ayala; Raffaele Scarpa
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

7.  Psoriatic arthritis: pharmacoeconomic considerations.

Authors:  Ignazio Olivieri; Lorenzo Giovanni Mantovani; Salvatore D'Angelo; Angela Padula; Simona de Portu
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

8.  Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses.

Authors:  Abrar A Qureshi; Hyon K Choi; Arathi R Setty; Gary C Curhan
Journal:  Arch Dermatol       Date:  2009-04

Review 9.  Treatment recommendations for psoriatic arthritis.

Authors:  C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

10.  The association between body mass index and arthritis among US adults: CDC's surveillance case definition.

Authors:  Jamie M Zakkak; Diane B Wilson; Jack O Lanier
Journal:  Prev Chronic Dis       Date:  2009-03-16       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.